This work was supported by the following: grants to T.H. - NIH / National Cancer Institute, CA14195 and CA082683; and fellowships to L.A.P. - Department of Defense
Prostate Cancer Research Program (PCRP), DoD - W81XWH -08-1-0209, and NIH / National Cancer Institute, 5T32CA009523 - 28.
The work was supported by the U.S. Assistant Secretary of Defense for Health Affairs through
the Prostate Cancer Research Program under Award No.
The research was supported by the National Cancer Institute, the Department of Defense
Prostate Cancer Research Program, the Fondation de France, and the Fédération Nationale des Centres de Lutte contre le Cancer.
Not exact matches
Study groups were drawn from the Icelandic
Cancer Registry; CAPS1, a population - based study of prostate cancer patients in Sweden; the Prostate Cancer Specialized Program of Research Excellence (SPORE) at Northwestern University; and the Flint Men's Health Study and the Prostate Cancer Genetics Project, both of the University of Mic
Cancer Registry; CAPS1, a population - based study of
prostate cancer patients in Sweden; the Prostate Cancer Specialized Program of Research Excellence (SPORE) at Northwestern University; and the Flint Men's Health Study and the Prostate Cancer Genetics Project, both of the University of M
prostate cancer patients in Sweden; the Prostate Cancer Specialized Program of Research Excellence (SPORE) at Northwestern University; and the Flint Men's Health Study and the Prostate Cancer Genetics Project, both of the University of Mic
cancer patients in Sweden; the
Prostate Cancer Specialized Program of Research Excellence (SPORE) at Northwestern University; and the Flint Men's Health Study and the Prostate Cancer Genetics Project, both of the University of M
Prostate Cancer Specialized Program of Research Excellence (SPORE) at Northwestern University; and the Flint Men's Health Study and the Prostate Cancer Genetics Project, both of the University of Mic
Cancer Specialized
Program of
Research Excellence (SPORE) at Northwestern University; and the Flint Men's Health Study and the
Prostate Cancer Genetics Project, both of the University of M
Prostate Cancer Genetics Project, both of the University of Mic
Cancer Genetics Project, both of the University of Michigan.
His most recently awarded grants are from the Agency for Health Care
Research and Quality, where he is Co-PI of the
program project grant, «Eliminating Racial Disparities in Health,» and from the Centers for Disease Control where he is PI of a constituent case - case project comparing
prostate cancer outcomes among African Americans and Caucasians.
At the Sidney Kimmel Comprehensive
Cancer Center, Dr. Nelson has served as the Associate Director for Translational Research and the Co-Director of the Prostate Cancer Program, and acts in a leadership role for the National Cancer Institute - funded Howard University Cancer Center - Sidney Kimmel Comprehensive Cancer Center Partnership Program, dedicated to building cancer research capabilities at Howard and to enhancing minority subject recruitment to cancer - research programs at Johns Ho
Cancer Center, Dr. Nelson has served as the Associate Director for Translational
Research and the Co-Director of the Prostate Cancer Program, and acts in a leadership role for the National Cancer Institute - funded Howard University Cancer Center - Sidney Kimmel Comprehensive Cancer Center Partnership Program, dedicated to building cancer research capabilities at Howard and to enhancing minority subject recruitment to cancer - research programs at Johns
Research and the Co-Director of the
Prostate Cancer Program, and acts in a leadership role for the National Cancer Institute - funded Howard University Cancer Center - Sidney Kimmel Comprehensive Cancer Center Partnership Program, dedicated to building cancer research capabilities at Howard and to enhancing minority subject recruitment to cancer - research programs at Johns Ho
Cancer Program, and acts in a leadership role for the National
Cancer Institute - funded Howard University Cancer Center - Sidney Kimmel Comprehensive Cancer Center Partnership Program, dedicated to building cancer research capabilities at Howard and to enhancing minority subject recruitment to cancer - research programs at Johns Ho
Cancer Institute - funded Howard University
Cancer Center - Sidney Kimmel Comprehensive Cancer Center Partnership Program, dedicated to building cancer research capabilities at Howard and to enhancing minority subject recruitment to cancer - research programs at Johns Ho
Cancer Center - Sidney Kimmel Comprehensive
Cancer Center Partnership Program, dedicated to building cancer research capabilities at Howard and to enhancing minority subject recruitment to cancer - research programs at Johns Ho
Cancer Center Partnership
Program, dedicated to building
cancer research capabilities at Howard and to enhancing minority subject recruitment to cancer - research programs at Johns Ho
cancer research capabilities at Howard and to enhancing minority subject recruitment to cancer - research programs at Johns
research capabilities at Howard and to enhancing minority subject recruitment to
cancer - research programs at Johns Ho
cancer -
research programs at Johns
research programs at Johns Hopkins.
The work was supported by the National Institutes of Health (NIH) Genomics Based Drug Discovery Consortium, the National
Cancer Institute Integrative
Cancer Biology
Program, the Howard Hughes Medical Institute, the Claudia Adams Barr
Program in
Cancer Research Innovative Basic Science
Research Program, the American Society of Clinical Oncology Conquer
Cancer Foundation Young Investigator Award, and the
Prostate Cancer Foundation.
PCF created the Young Investigator Awards
program with one goal: to identify a cohort of future
research leaders who will keep the field of
prostate cancer research vibrant with new ideas.
Dr. Dean Ornish revolutionized medicine by directing clinical
research proving — for the first time — that heart disease and early - stage
prostate cancer may be stopped or even reversed by his
program of comprehensive lifestyle changes, without drugs or surgery.
Men with the highest levels of exercise before their diagnosis were 30 percent less likely to die of their
prostate cancer than those who exercised the least, according to a team led by Ying Wang, senior epidemiologist at the
cancer society's epidemiology
research program.
Westmont, Illinois About Blog
Prostate Cancer Foundation of Chicago is a non-profit organization dedicated to improving quality of care and quality of life by funding patient support
programs, clinical
research as well as professional and public education.
Westmont, Illinois About Blog
Prostate Cancer Foundation of Chicago is a non-profit organization dedicated to improving quality of care and quality of life by funding patient support
programs, clinical
research as well as professional and public education.